|
|
|
Insider
Information: |
Hallal David |
Relationship: |
Director |
City: |
Cheshire |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
2,992,151 |
|
Indirect Shares
|
17,647,006 |
|
|
Direct
Value |
$38,846,310 |
|
|
Indirect Value
|
$34,343,989 |
|
|
Total
Shares |
20,639,157 |
|
|
Total
Value |
$73,190,298 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
Percentage
Gain/Loss : |
0.0%
|
-122.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alexion Pharmaceuticals Inc |
ALXN |
CEO, Director |
2016-08-08 |
189,266 |
2014-12-18 |
113,122 |
Premium* |
|
Scholar Rock Holding Corp |
SRRK |
|
2024-06-27 |
304,095 |
2019-09-18 |
0 |
Premium* |
|
Allovir Inc |
ALVR |
|
2024-06-06 |
2,143,662 |
2024-06-06 |
17,533,884 |
Premium* |
|
Seer, Inc. |
SEER |
|
2024-06-12 |
355,128 |
|
0 |
Premium* |
|
Iteos Therapeutics, Inc. |
ITOS |
Director |
2022-06-09 |
0 |
2021-12-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALXN |
Alexion Pharmaceuticals I... |
SVP, Global Commercial Ops |
|
2012-06-15 |
4 |
OE |
$11.92 |
$170,551 |
D/D |
14,308 |
77,518 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP. Global Commercial Ops |
|
2012-07-27 |
4 |
S |
$106.14 |
$5,445,908 |
D/D |
(50,555) |
62,655 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP. Global Commercial Ops |
|
2012-07-27 |
4 |
OE |
$17.65 |
$882,500 |
D/D |
50,000 |
113,210 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP. Global Commercial Ops |
|
2012-07-31 |
4 |
S |
$104.99 |
$71,393 |
D/D |
(680) |
61,975 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP. Global Commercial Ops |
|
2012-10-24 |
4 |
OE |
$8.16 |
$85,680 |
D/D |
10,500 |
72,475 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP. Global Commercial Ops |
|
2012-10-24 |
4 |
OE |
$8.16 |
$85,680 |
D/D |
10,500 |
72,475 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP. Global Commercial Ops |
|
2013-01-28 |
4 |
S |
$94.50 |
$59,724 |
D/D |
(632) |
71,843 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP. Global Commercial Ops |
|
2013-01-29 |
4 |
S |
$94.32 |
$48,292 |
D/D |
(512) |
71,331 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-02-04 |
4 |
S |
$95.68 |
$200,537 |
D/D |
(2,085) |
69,246 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,400 |
74,646 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-06-05 |
4 |
OE |
$8.16 |
$204,281 |
D/D |
15,008 |
89,654 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-07-12 |
4 |
OE |
$17.65 |
$882,500 |
D/D |
50,000 |
139,654 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-07-12 |
4 |
AS |
$120.00 |
$6,000,000 |
D/D |
(50,000) |
89,654 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-07-30 |
4 |
S |
$110.86 |
$82,702 |
D/D |
(746) |
88,908 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-08-05 |
4 |
S |
$116.87 |
$85,315 |
D/D |
(730) |
88,178 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-10-28 |
4 |
AS |
$122.79 |
$3,691,504 |
I/I |
(30,000) |
88,178 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-10-28 |
4 |
OE |
$17.98 |
$539,400 |
I/I |
30,000 |
118,178 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-10-28 |
4 |
AS |
$122.79 |
$2,214,901 |
D/D |
(18,000) |
88,178 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-10-28 |
4 |
OE |
$17.98 |
$323,640 |
D/D |
18,000 |
106,178 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-09 |
4 |
OE |
$17.98 |
$192,476 |
D/D |
10,705 |
120,383 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-09 |
4 |
OE |
$17.98 |
$263,173 |
I/I |
14,637 |
124,315 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-09 |
4 |
AS |
$127.63 |
$1,868,120 |
I/I |
(14,637) |
109,678 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-09 |
4 |
AS |
$127.63 |
$1,366,279 |
D/D |
(10,705) |
109,678 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-18 |
4 |
OE |
$17.98 |
$131,164 |
D/D |
7,295 |
116,973 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Commercial Officer |
|
2013-12-18 |
4 |
AS |
$127.61 |
$1,960,472 |
I/I |
(15,363) |
109,678 |
0 |
- |
|
130 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|